Novel nitric oxide synthase inhibitors: A patent review

Expert Opinion on Therapeutic Patents

Volumn 21, Issue 4, 2011, Pages 537-560

  Joubert, Jacques ^a   Malan, Sarel F ^a  

^a UNIVERSITY OF THE WESTERN CAPE   (South Africa)

Author keywords

Drug discovery; NOS inhibitors; NOS isoforms; therapeutic applications

Indexed keywords

ENDOTHELIAL NITRIC OXIDE SYNTHASE INHIBITOR; INDUCIBLE NITRIC OXIDE SYNTHASE INHIBITOR; NEURONAL NITRIC OXIDE SYNTHASE INHIBITOR; NITRIC OXIDE SYNTHASE INHIBITOR; UNCLASSIFIED DRUG;

BIOASSAY; DRUG BIOAVAILABILITY; DRUG DESIGN; DRUG INDUSTRY; DRUG SYNTHESIS; HUMAN; NERVE FIBER; NONHUMAN; PATENT; REVIEW;

ANIMALS; DRUG DESIGN; ENZYME INHIBITORS; HUMANS; NITRIC OXIDE SYNTHASE; PATENTS AS TOPIC;

EID: 79952938814     PISSN: 13543776     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543776.2011.556619     Document Type: Review

References (141)

1. Thomas DD, Ridnour LA, Isenberg JS, et al. The chemical biology of nitric oxide: Implications in cellular signaling. Free Radical Biol Med 2008;45(1):18-31 • This review discusses the relationship between the fundamental chemistry of NO and the important influences on cellular microenvironment
2. Moncada S, Palmer RM, Higgs EA. Nitric oxide: Physiology, pathophysiology, and pharmacology. Pharmacol Rev 1991;21(2):109-42
3. Martin IN, Woodward JJ, Winter MB, et al. Design and synthesis of C5 Methylated L-arginine analogues as active site probes for nitric oxide synthase. J Am Chem Soc 2007;129:12563-70 (Pubitemid 47598257)
4. Dawson VL, Dawson TM, Lomdon ED, et al. Nitric oxide mediates glutamate neurotoxicicty in primary cortical cultures. Proc Natl Acad Sci 1991;88:6368-71 (Pubitemid 21914947)
5. Kerwin JF, Lancaster JR, Feldamn PL. Nitric oxide: A new paradigm for second messengers. J Med Chem 1995;38:4343-62 •• This review gives an in-depth overview of the molecular mechanism of NOS-mediated NO biosynthesis
6. Knowles RG, Moncada S. Nitric oxide synthases in mammals. Biochem J 1994;298(2):249-58 (Pubitemid 24072462)
7. Cary SPL, Winger JA, Derbyshire ER, et al. Nitric oxide signaling: No longer simply on or off. Trends Biochem Sci 2006;31(4):231-9
8. Hoffman BB, Taylor P. Goodman and gilman's. The pharmacological basis of therapeutics. Chapter 6: Neurotransmission. McGraw-Hill, New York; 2001. p. 148
9. Roman LJ, Mattasek P, Masters BSS. Intrinsic and extrinsic modulation of nitric oxide synthase activity. Chem Rev 2002;102:1179-89 • This review is focused on the modes of regulation of the isoforms of NOS. The biochemistry and physiology of the NOS isoforms have revealed various interesting differences among the isoforms indicating that several regulatory mechanisms must be operating (Pubitemid 35377608)
10. Marletta MA. Nitric oxide synthase structure and mechanism. J Biol Chem 1993;268:12231-4 (Pubitemid 23182366)
11. Steur DJ. Mammalian nitric oxide synthase. Biochemica et Biophysica Acta (BBA) Bioenergetics 1999;1411:217-30
12. Alderton WK, Cooper CE, Knowles RG. Nitric oxide synthases: Structure function and inhibition. Biochem J 2001;357:593-615 •• A comprehensive and up-to-date review on the advances in NOS structure, function and inhibition (Pubitemid 32735142)
13. Knowles RG, Palacios M, Palmer MRJ, et al. Formation of nitric oxide from L-Arginine in the central nervous system: A transduction mechanism for stimulation of the soluble guanylate cyclase. Proc Natl Acad Sci 1989;86:5159-62 (Pubitemid 19182253)
14. Uehara T, Nakamura T, Yao D, et al. S-Nitrosylated protein-disulphide isomerase links protein misfolding to neurodegeneration. Nature 2006;441(7092):513-17 (Pubitemid 44050153)
15. Kim SF, Huri DA, Snyder SH. Inducible nitric oxide synthase binds, S-nitrosylates, and activates cyclooxygenase-2. Science 2005;310(5756):1966-70 (Pubitemid 43005992)
16. Rosen GM, Tsai P, Pou S. Mechanism of free-radical generation by nitric oxide synthase. Chem Rev 2002;102(1):191-200 • This is a comprehensive review that discusses NOS as an enzyme which participates in secondary metabolism and free-radical generation
17. Wang Y, Newton DC, Robb GB, et al. RNA diversity has profound effects on the translation of neuronal nitric oxide synthase. Proc Natl Acad Sci USA 1999;96:12150-5 (Pubitemid 29502873)
18. Brenman JE, Chao DS, Gee SH, et al. Interaction of nitric oxide synthase with the postsynaptic density protein PSD-95 and alpha1-syntrophin mediated by PDZ domains. Cell 1996;84:757-67 (Pubitemid 26094205)
19. Silvagno F, Xia H, Bredt DS. Neuronal nitric-oxide synthase-mu, an alternatively spliced isoform expressed in differentiated skeletal muscle. J Biol Chem 1996;271:11204-8
20. Magee T, Fuentes AM, Garban H, et al. Cloning of a novel neuronal nitric oxide synthase expressed in penis and lower urinary tract. Biochem Biophys Res Commun 1996;226:145-51 (Pubitemid 26332177)
21. Ogura T, Yokoyama T, Fujisawa, et al. Structural diversity of neuronal nitric oxide synthase mRNA in the nervous system. Biochem Biophys Res Commun 1993;193:1017-22
22. Fujisawa H, Ogura T, Kurashima Y, et al. Expression of two types of nitric oxide synthase mRNA in human neuroblastoma cell lines. J Neurochem 1994;63:140-5 (Pubitemid 24184911)
23. Brenman JE, Xia H, Chao DS, et al. Regulation of neuronal nitric oxide synthase through alternative transcripts. Dev Neurosci 1997;19:224-31 (Pubitemid 27230840)
24. Kolesnikov YA, Pan YX, Babey AM, et al. Functionally differentiating two neuronal nitric oxide synthase isoforms through antisense mapping: Evidence for opposing NO actions on morphine analgesia and tolerance. Proc Natl Acad Sci USA 1997;94:8220-5 (Pubitemid 27343804)
25. Eliasson MJ, Blackshaw S, Schell MJ, et al. Neuronal nitric oxide synthase alternatively spliced forms: Prominent functional localizations in the brain. Proc Natl Acad Sci USA 1997;97:3396-401 (Pubitemid 27157323)
26. Hemmens B, Woschitz S, Pitters E, et al. The protein inhibitor of neuronal nitric oxide synthase: Characterization of its action on pure nitric oxide synthases. FEBS Lett 1998;430:397-400 (Pubitemid 28337952)
27. Christopherson KS, Hillier BJ, Lim WA, et al. PSD-95 assembles a ternary complex with the N-methyl-d-aspartic acid receptor and a bivalent neuronal NO synthase PDZ domain. J Biol Chem 1999;274:27467-73
28. Boughton SNK, Tinker AC. Inhibitors of nitric oxide synthase in inflammatory arthritis. IDrugs 1998;1:321-33 •• An excellent review on selective iNOS inhibitors and the activity of these compounds in animal models of arthritis (Pubitemid 128751608)
29. Endres M, Laufs U, Liao JK, et al. Targeting eNOS for stroke protection. Trends Neurosci 2004;27(5):283-9 (Pubitemid 38529957)
30. Braam B, Verhaar MC. Understanding eNOS for pharmacological modulation of endothelial function: A translational view. Curr Pharm 2007;13(17):1727-40 (Pubitemid 46979711)
31. Larson AA, Kovacs KJ, Cooper JC, et al. Transient changes in the synthesis of nitric oxide result in long-term as well as short-term changes in acetic acid-induced writhing in mice. Pain 2000;86:103-11 • This review shows that commercially available inhibitors of nNOS induce both long- as well as short-term changes in nociception. This is consistent with the notion that NO is important in plasticity of nociceptive pathways (Pubitemid 30211709)
32. Tafi A, Angeli L, Venturini G, et al. Computational studies of competitive inhibitors of nitric oxide synthase (NOS) enzymes: Towards the development of powerful and isoform-selective inhibitors. Curr Med Chem 2006;13(16):1929-46
33. Salerno L, Sorrenti V, Di Giacomo C, et al. Progress in the development of selective nitric oxide synthase (NOS) inhibitors. Curr Pharm Des 2002;8(3):177-200 (Pubitemid 34449889)
34. Vallance P, Leiper J. Blocking nO synthesis: How, where and why? Nat Rev Drug Discov 2002;1(12):939-50 • This review focuses on the rationale and potential for approaches that reduce NO synthesis, which have led to the development of several compounds entering clinical trials (Pubitemid 37361600)
35. Muscara MN, Wallace JL. Nitric oxide V. Therapeutic potential of nitric oxide donors and inhibitors. Am J Physiol 1999;276:1313-16
36. Ogden JE, Moore PK. Inhibition of nitric oxide synthase-potential for a novel class of therapeutic agent. Trends Biotech 1995;13:70-8 • Provides an overview of the different assay methods used to determine NOS activity
37. Griffith OW, Kilbourn RG. Nitric oxide synthase inhibitors: Amino acids. Methods Enzymol 1996;268:375-92 (Pubitemid 26286380)
38. Southan GJ, Szabo C. Selective pharmacological inhibition of distinct nitric oxide synthase isoforms. Biochem Pharmacol 1996;51(4):383-94 (Pubitemid 26071171)
39. Wilcock DM, Lewis MR, Van Nostrand WE, et al. Progression of amyloid pathology to Alzheimer's disease pathology in an amyloid precursor protein transgenic mouse model by removal of nitric oxide synthase 2. J Neurosci 2008;28(7):1537-45 • This study shows that removal of NOS2 from an APP transgenic mouse results in development of a much greater spectrum of Alzheimer's disease-like pathology and behavioral impairments (Pubitemid 351287042)
40. Babbedge RC, Bland-Ward PA, Hart SL, et al. Inhibition of rat cerebellar nitric oxide synthase by 7-nitro indazole and related substituted indazoles. Br J Pharmacol 1993;1(10):225-8 (Pubitemid 23257783)
41. Babu BR, Griffith OW. Design of the isoform-selective inhibitors of nitric oxide synthase. Curr Opin Chem Biol 1998;2:491-500 (Pubitemid 128645702)
42. Pekiner C, Kelicen P, Uma S, et al. Two nitric oxide synthase inhibitors: Pyridoxal aminoguanidine and 8-quinolinecarboxylic hydrazide selectively inhibit basal but not agonist stimulated release of nitric oxide in rat aorta. Pharmacol Res 2002;46:317-20 (Pubitemid 35304480)
43. Handy RLC, Wallace P, Gaffen ZA, et al. The antinociceptive effect of 1-(2-trifluoromethylphenyl) imidazole (TRIM), a potent inhibitor of neuronal nitric oxide synthase in vitro, in the mouse. Br J Pharmacol 1995;116:2349-50
44. Zhang ZG, Reif D, MacDonald WX, et al. ARL 17477, a potent and selective neuronal NOS inhibitor decreases infarct volume after transient middle cerebral artery occlusion in rats. J Cereb Blood Flow Metab 1996;16:599-604 (Pubitemid 26227068)
45. Neuraxon, Inc. Substituted indole compounds having NOS inhibitory activity. US20060258721; 2006
46. Neuraxon, Inc. Substituted indole compounds having NOS inhibitory activity. WO2007063418; 2007
47. Neuraxon, Inc. 1,5 and 3,6-substituted indole compounds having NOS inhibitory activity. WO2007118314; 2007
48. Neuraxon, Inc. 3,5-Substituted indole compounds having NOS and norepinephrine reuptake inhibitory activity. WO2009062318; 2009
49. Neuraxon, Inc. Indole compounds and methods for treating visceral pain. WO2009062319; 2009
50. Hevel JM, Marletta MA. Nitric oxide synthase assays. Methods Enzymol 1994;133:250-8 • This paper discusses in-depth the procedure for measuring NOS activity utilizing the hemoglobin capture assay
51. Neuraxon, Inc. Substituted benzimidazole compounds with dual NOS inhibitory activity and mu-opoid agonist activity. WO2007017764; 2007
52. Neuraxon, Inc. Quinolone and tetrahydroquinolone and related compounds having NOS inhibitory activity. US20080234237; 2008
53. Neuraxon, Inc. Benzoxazines, benzothiazines, and related compounds having NOS inhibitory activity. WO2010000073; 2010
54. Northwestern University. Heteroaromatic selective inhibitors of neuronal nitric oxide synthase. WO20050107369; 2005
55. Northwestern University. Heteroaromatic selective inhibitors of neuronal nitric oxide synthase. WO2005026111; 2005
56. NOS inhibitors for the treatment of motor deficit disorders. WO2008036294; 2008
57. North Western University. Potent and highly selective heteroaromatic inhibitors of neuronal nitric oxide synthase. US20080108814; 2008 • This article describes the synthesis and nNOS inhibition of the most potent and selective nNOS inhibitor reported to date
58. Ji H, Li H, Martasek P, et al. Discovery of Highly Potent and Selective Inhibitors of Neuronal Nitric Oxide Synthase by Fragment Hopping. J Med Chem 2009;52:779-97 •• This study shows the establishment of a new fragment-based de novo design strategy called fragment hopping. Using this approach, pyrrolidinomethyl aminopyridines were designed and synthesized, which showed nanomolar nNOS inhibitory potency and > 1000-fold nNOS selectivity over eNOS
59. Lawton GR, Ranaivo HR, Chic LK, et al. Analogues of 2-aminopyridine-based selective inhibitors of neuronal nitric oxide synthase with increased bioavailability. Bioorg Med Chem 2009;17:2371-80
60. Xue F, Fang J, Lewis WW, et al. Potent and selective neuronal nitric oxide synthase inhibitors with improved cellular permeability. Bioorg Med Chem 2010;20:544-57
61. Northwestern University. Potent and selective neuronal nitric oxide synthase inhibitors with improved membrane permeability. US201001902320; 2010
62. Northwestern University. Aminopyridine dimer compounds, compositions and related methods for neuronal nitric oxide synthase inhibition. US20100203613; 2010
63. Haung H, Martasek P, Roman LJ, et al. N-nitroarginine-containing dipeptide amides. Potent and highly selective inhibitors of neuronal nitric oxide synthase. J Med Chem 1999;42:3147-53 (Pubitemid 29384050)
64. Northwestern University. Selective neuronal nitric oxide synthase inhibitors. US20030119751; 2003
65. Northwestern University. NOS inhibitors for treatment of motor deficit disorders. WO2008036294; 2008
66. Northwestern University. Selective neuronal nitric oxide synthase inhibitors. US7470815: 2008
67. Hah JM, Roman LJ, Martasek P, et al. Reduced amide bond isosteric peptidomimetics. (4S)-N-(4-Amino-5- [aminoalkyl]aminopentyl)-N'- nitroguanidines, potent and highly selective inhibitors of neuronal nitric oxide synthase. J Med Chem 2001;44:2667-70 (Pubitemid 32852155)
68. Hah JM, Martasek P, Roman LJ, et al. Aromatic reduced amide bond peptidomimetics as selective inhibitors of neuronal nitric oxide synthase. J Med Chem 2003;46:1661-9 • This study reports reduced amide bond pseudo dipeptide analogs with a high degree of lipophilicity and high potency for nNOS as well as high selectivity of nNOS over endothelial NOS and inducible NOS (Pubitemid 36444219)
69. Schmidt HH, Walter U. NO at work. Cell 1994;78:919-25 (Pubitemid 24292320)
70. Titheradge MA. Nitric oxide in septic shock. Biochim Biophys Acta 1991;1411:437-55
71. Hobbs AJ, Higgs A, Moncada S. Inhibition of nitric oxide synthase as a potential therapeutic target. Annu Rev Pharmacol Toxicol 1999;39:191-220 (Pubitemid 29222557)
72. Mete A, Connolly S. Inhibitors of the NOS enzymes: A patent review. IDrugs 2003;6:57-65 •• A previous patent review of NOS inhibitors up to 2003 (Pubitemid 46780290)
73. Moncada S, Higgs EA. Molecular mechanisms and therapeutic strategies related to nitric oxide. FASEB J 1995;9:1319-30
74. Garvey EP, Oplinger JA, Furfine ES, et al. 1400W is a slow, tight binding and highly selective inhibitor of inducible nitric-oxide synthase in vitro and in vivo. J Biol Chem 1997;272:4959-63 (Pubitemid 27090046)
75. Young RJ, Beams RM, Carter K, et al. Inhibition of inducible nitric oxide synthase by acetamidine derivatives of hetero-substituted lysine and homolysine. Bioorg Med Chem Lett 2000;10:597-600 (Pubitemid 30162468)
76. Alderton WK, Angell AD, Craig C, et al. GW274150 and GW273629 are potent and highly selective inhibitors of inducible nitric oxide synthase in vitro and in vivo. Br J Pharmacol 2005;145:301-12 • This study showed that the effects of GW274150 and GW273629 in vivo were consistent with high selectivity for iNOS, as these inhibitors were of low potency against nNOS in the rat cerebellum and did not cause significant effects on blood pressure in mice. Both compounds show a high oral bioavailability (> 90%) in rats and mice (Pubitemid 40896075)
77. Beaton H, Hamley P, Nicholls DJ, et al. 3,4-Dihydro-1-isoquinolinamines: A novel class of nitric oxide synthase inhibitors with a range of isoform selectivity and potency. Bioorg Med Chem Lett 2001;11:1023-6 (Pubitemid 32319972)
78. Tinker AC, Beaton HG, Boughton-Smith N, et al. 1,2-Dihydro-4- quinazolinamines: Potent, highly selective inhibitors of inducible nitric oxide synthase which show anti-inflammatory activity in vivo. J Med Chem 2003;46:913-16 (Pubitemid 36423137)
79. Nishina K, Mikawa K, Kodoma S, et al. ONO1714, a new inducible nitric oxide synthase inhibitor, attenuates sepsis-induced diaphragmatic dysfunction in hamsters. Anesth Analg 2001;92:959-66 (Pubitemid 32239142)
80. Hansel RT, Kharitonov SA, Donnelly LE, et al. A selective inhibitor of inducible nitric oxide synthase inhibits exhaled breath nitric oxide in healthy volunteers and asthmatics. FASEB J 2003;16:1298-300
81. Habisch HJ, Gorren AC, Liang H, et al. Pharmacological interference with dimerization of human neuronal nitric-oxide synthase expressed in adenovirus-infected DLD-1 cells. Mol Pharmacol 2003;63:682-9 (Pubitemid 36297341)
82. Altana Pharma AG. Imidazo(4,5-B) pyridine-derivatives as inducible NO-synthase inhibitors. WO2005030768; 2005
83. Altana Pharma AG. Imidazopyridine-derivatives as inducible NO-synthase inhibitors. WO2005030770; 2005
84. Altana Pharma AG. Imidazolyl-substituted azabenzophenone compounds. WO2007039578; 2007
85. Altana Pharma AG. Imidazole-substituted benzophenone compounds. WO2007039580; 2007
86. Altana Pharma AG. Imidazolyl-substituted diazabenzophenone compounds. WO2007039581; 2007
87. Altana Pharma AG. Oxazolo[4,5-B] pyridine compounds as nitric oxide synthase inhibitors. WO2007045622; 2007
88. Altana Pharma AG. Imidazopyridine-derivatives as inducible NO-synthase inhibitors. WO2005030769; 2005
89. Altana Pharma AG. Imidazopyridine-derivatives as inducible NO-synthase inhibitors. WO2005030771; 2005
90. Altana Pharma AG. Alkoxypyridine-derivatives. US7138399; 2006
91. Altana Pharma AG. Imidazopyridine-derivatives as inducible NO-synthase inhibitors. US20090036482; 2009
92. Altana Pharma AG. Aminopyridine-derivatives. US7781453; 2010
93. Aventis Pharmaceuticals, Inc. Coumarins as iNOS inhibitors. WO2005026143; 2005
94. Aventis Pharmaceutical, Inc. Coumarins as iNOS inhibitors. US7538233; 2009
95. Bredt DS, Snyder SH. Isolation of nitric oxide synthase, a calmodulin-requiring enzyme. Proc Natl Acad Sci 1990;87:682-5
96. Nycomed GMBH. Aminoazepine derivatives as highly efficient inhibitors of the inducible nitric oxide synthase. WO2008031788; 2008
97. Nycomed GMBH. Imidazopyridine derivatives useful as iNOS inhibitors. US7790710; 2010
98. Schering. N-heterocyclic derivatives as NOS inhibitors. US20060094725; 2006
99. Schering. 1-(Pyridazin-3-yl)-imidazole derivatives as inhibitors of nitric oxide synthase (NOS). US7202263; 2007
100. Berlex Laboratories, Inc. N-Heterocyclic derivatives as NOS inhibitors. WO0114371; 2003
101. Berlex Laboratories, Inc. N-Heterocyclic derivatives as NOS inhibitors. WO0114371; 2005
102. Berlex Laboratories, Inc. N-Heterocyclic derivatives as NOS inhibitors. US6841674; 2005
103. Damiani P, Burini G. Fluorometric determination of nitrite. Talanta 1986;33:649-52
104. Seoul national university foundation. Pharmaceutical composition, health food composition and iNOS inhibitors, containing theopederin derivatives. WO2008072937; 2007
105. Pharmacia Corp. Amidino compounds useful as nitric oxide synthase inhibitors. US6914158; 2004
106. Pharmacia Corp. 2-Amino-2-alkyl- 4 hexenoic and hexynoic acid derivatives useful as nitric oxide synthase inhibitors. US20050256199; 2005
107. Pharmacia Corp. Combination therapy with inhibitors of inducible nitric oxide and alkylating agents. WO2005025620; 2005
108. Pharmacia Corp. Amidino compounds useful as nitric oxide synthase inhibitors. US7196118; 2007
109. Pharmacia Corp. 2-Amino-2-alkyl-5 heptenoic and heptynoic acid derivatives. WO2007203823; 2007
110. Erba Carlo Spa. New aryl- and heteroarylathenylene derivatives and process for their preparation. WO1991013055; 1991
111. Searle & CO; Currie Mark G. Amidino derivatives useful as nitric oxide synthase inhibitors. WO1995025717; 1995
112. Carre MC, Mahieuxe JC, Andre JC, et al. Fluorometric nitrate analysis using 2,3-diaminonaphthalene: An improvement of the method. Analusis 1999;27:835-8
113. Kalypsys Incorporation. Inducible nitric oxide synthase dimerization inhibitors. US20060116515; 2006
114. Kalypsys Incorporation. Inducible nitric oxide synthase dimerization inhibitors. US2006060424; 2006
115. Kalypsys Incorporation. Salts of inducible nitric oxide synthase dimerization inhibitors. US20070197609; 2007
116. Kalypsys Incorporation. Imidazole derivatives as nitric oxide synthase dimerization inhibitor. WO2007062410; 2007
117. Kalypsys Incorporation. Methods of preparing 2-imidazol-1-yl-4-methyl-6- pyrrolidin-2-yl-pyrimidine and 4-(1- alkylpyrrolodin-2-yl)-2-(1H-imidazol-1- yl)-6methylpyrimidine derivatives. US20080293942; 2008
118. Kalypsys Incorporation. Quinolones useful as inducible nitric oxide synthase inhibitors. WO2007117778; 2007
119. Kalypsys Incorporation. Isoquinolines useful as inducible nitric oxide synthase inhibitors. WO2008103615; 2008
120. Kalypsys Incorporation. Topical pharmaceutical formulation comprising an iNOS inhibitor for the treatment of disease. WO2008086176; 2008
121. Kalypsys Incorporation. 4-[heterocyclylmethyl]- 8-fluoro-quinolin-2-ones useful as nitric oxide synthase inhibitors. WO2009029625; 2009
122. Kalypsys Incorporation. Diarylamine-substituted quinolones useful as inducible nitric oxide synthase inhibitors. WO2009029617; 2009
123. Kalypsys Incorporation. Heterobicyclic-substituted quinolones useful as nitric oxide synthase inhibitors. WO2009029595; 2009
124. Luvone T, D'Acquisto F, Van Osselaer N, et al. Evidence that inducible nitric oxide synthase is involved in LPS-induced plasma leakage in rat skin through the activation of nuclear factor-kappaB. Br J Pharmacol 1998;123:1325-30 • This study indicated that LPS-induced plasma leakage in rat skin is modulated by NO mainly produced by the inducible isoform of NOS. Furthermore, the suppression of plasma leakage by PDTC, an inhibitor of NF-kB activation, is correlated to the inhibition of iNOS protein expression (Pubitemid 28143131)
125. Kalypsys Incorporation. Treatment of inflammation and related disorders by activation of the unfolded protein response. WO2007084868; 2007
126. Kalypsys Incorporation. Novel 2-oxo-1,2,3,4-tetrahydropyrimidines, bicyclic pyrimidine diones and imidazolidine-2,4-diones useful as inducible nitric oxide synthase inhibitors. WO2007101213; 2007
127. Pfizer, Inc. S-[2[(1-Iminoethyl)amino] ethyl]-2-methyl-L-cysteine maleate hydrochloride crystalline salt. US7767850; 2010
128. Pharmacia Corporation. Amidino compounds and salts thereof useful as nitric oxide synthase inhibitors. US6403830; 2002
129. AstraZeneca. Anti-inflammatory 3-Aryl-3-thiazolyl-alkylamines. WO2004041794; 2004
130. AstraZeneca. Novel compounds. WO2004009580; 2004
131. AstraZeneca. Heteroarylheteroallkylamine derivatives and their use as inhibitors of nitric oxide synthase. WO03011831; 2004
132. AstraZeneca. Arylheteroalkylamine derivatives and their use as inhibitors of nitric oxide synthase. WO03011210; 2005
133. AstraZeneca. Compounds for the inhibition of nitric oxide synthase. US7276528; 2007
134. AstraZeneca. Substituted thiophene compounds. US7329686; 2008
135. Forstermann U, Schmidt HHHW, Kohlhaas KL, et al. Induced RAW 264.7 macrophages express soluble and particulate nitric oxide synthase: Inhibition by transforming growth factor-beta. Eur J Pharm 1992;225:161-5
136. Ignarro LJ. Nitric oxide as a unique signaling molecule in the vascular system: A historical overview. J Physiol Pharmacol 2002;53:503-14 • This review discusses novel NO donor drugs for clinical use for the treatment of essential hypertension, stroke, coronary artery disease, vascular complications of diabetes, impotency and other disorders involving the vascular system (Pubitemid 36014797)
137. Bonetti PO, Lerman LO, Lerman A. Endothelial dysfunction: A marker of atherosclerotic risk. Arterioscler Thromb Vasc Biol 2003;23:168-75 (Pubitemid 36231924)
138. Heitzer T, Schlinzig T, Krohn K, et al. Endothelial dysfunction, oxidative stress, and risk of cardiovascular events in patients with coronary artery disease. Circulation 2001;104:2673-8 (Pubitemid 33108132)
139. Cai H, Harrison DG. Endothelial dysfunction in cardiovascular diseases: The role of oxidant stress. Circ Res 2000;87:840-4
140. Van der Schyf CJ, Youdim MB. Multifunctional drugs as neurotherapeutics. Neurotherapeutics 2009;6:1-201 • A review of the design and progress made on multifunctional drugs and why this approach may have merit in designing therapeutics for neurodegenerative disorders
141. Silverman RB. Design of selective neuronal nitric oxide synthase inhibitors for the prevention and treatment of neurodegenerative diseases. Acc Chem Res 2009;42(3):439-51 •• This study describes that the cis and trans isomers of a series of amino pyrrolidinomethyl 2-aminopyridine derivatives had different binding conformations in the NOS active site, revealing some critical structural requirements for ligand binding.